Regeneron Pharmaceuticals Inc $322.18

up +17.67


30/7/2014 04:00 PM  |  NASDAQ : REGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get REGN Trend Analysis - it has outperformed the S&P 500 by 1%

Partner Headlines

  1. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD
  2. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  3. Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples

    IBD
  4. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  5. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD
  6. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD
  7. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD
  8. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following ...

    Benzinga
  9. Benzinga's Top #PreMarket Gainers

    Benzinga
  10. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of ...

    Benzinga
  11. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  12. Pharmas Soar To New Highs

    IBD
  13. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  14. Stocks Rise In Strong Turnover; Netflix Soars On Upgrade

    IBD
  15. Regeneron Rises As Sanofi Raises Stake In Biotech

    IBD
  16. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  17. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  18. EYLEA Injection Recommended For Approval Regarding Treatment Of Visual ...

    Benzinga
  19. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  20. Major Indexes Narrowly Lower As Actavis Rallies

    IBD
  21. Regeneron Shares Fall Following BMO's Note Of Roche Preference

    Benzinga
  22. US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

    Benzinga
  23. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  24. Valeant EPS Tops, Sales Miss

    IBD
  25. Valeant Reports Mixed Q1 Amid Drug Earnings Bonanza

    IBD
  26. Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed

    IBD
  27. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  28. RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

    Benzinga
  29. UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals ...

    Benzinga
  30. Benzinga's Top Initiations

    Benzinga
  31. Top 40 Upcoming Earnings Releases

    Benzinga
  32. Biotechs Struggling To Find A Bottom

    Benzinga
  33. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  34. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  35. Cholesterol drug meets goal

    IBD
  36. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  37. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  38. Gilead Adds To Biotech Woes

    IBD
  39. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  40. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  41. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  42. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  43. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  44. US Stock Futures Rise; GDP, Jobless Claims Data In Focus

    Benzinga
  45. Netflix, Other Big Cap Growth Stocks Offer Buy Points

    IBD
  46. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  47. UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals

    Benzinga
  48. Regeneron falls on FDA probe

    IBD
  49. Nasdaq Lags As Stock Market Closes Lower

    IBD
  50. Early Gains Fade; E-House Breaks Out But Biotechs Stumble

    IBD
Trading Center